Undergraduate Research Journal
Volume 25

Article 8

2021

Assessment Tools in Clinical and Counseling Psychology
Alea Reifenrath
University of Nebraska at Kearney

Follow this and additional works at: https://openspaces.unk.edu/undergraduate-research-journal
Part of the Clinical Psychology Commons, and the Counseling Psychology Commons

Recommended Citation
Reifenrath, Alea (2021) "Assessment Tools in Clinical and Counseling Psychology," Undergraduate
Research Journal: Vol. 25, Article 8.
Available at: https://openspaces.unk.edu/undergraduate-research-journal/vol25/iss1/8

This Article is brought to you for free and open access by the Office of Undergraduate Research & Creative Activity
at OpenSPACES@UNK: Scholarship, Preservation, and Creative Endeavors. It has been accepted for inclusion in
Undergraduate Research Journal by an authorized editor of OpenSPACES@UNK: Scholarship, Preservation, and
Creative Endeavors. For more information, please contact weissell@unk.edu.

ASSESSMENT TOOLS IN CLINICAL AND COUNSELING PSYCHOLOGY
Alea Reifenrath
Mentor: Dr. Chris Waples, Department of Psychology
OVERVIEW
“Evidence-based” has become a keyword in the realm of clinical and counseling
psychology. Hundreds of thousands of articles have been written on the topic. It represents a focus
on empirical evidence and best practice. This key phrase can be tied to many facets in psychology
and health care, such as evidence-based practice and evidence-based treatment. One area which is
often overlooked is evidence-based assessment (EBA). EBA is defined as the use of standardized
assessment tools that have research support for their psychometric properties (Jensen-Doss &
Hawley, 2010). Assessment is a key aspect of the therapeutic process. It involves screening
individuals who are at risk for a particular mental health concern, determining the severity of a
given issue, and monitoring the effectiveness of treatment. EBA allows for best practice by
providing empirically sound, valid, reliable measures of assessment. Jensen-Doss and Hawley
(2010) point out that assessment is crucial to treatment, as all treatment is based on assessment and
diagnosis. Therefore, they claim, some element of EBA must be included for evidence-based
treatment to be fully effective and accurate.
Despite the potential benefits of EBA, it has received little attention. While there is a trend
toward evidence-based practice and evidence-based treatment, EBA seems to remain unnoticed
(Beidas et al., 2015). As many as 83% of psychiatrists report never using standardized assessment
tools (Jensen-Doss & Hawley, 2010). Greater use can be seen among psychologists and mental
health practitioners, but the majority still report never using such instruments.
A myriad of reasons can be cited for not using EBA tools. Many practical concerns exist,
such as limited access to tests, high paperwork burdens, and intense time demands (Beidas et al.,
2015). These concerns do make sense, particularly in understaffed environments and small private
practice settings. Assessment tools also face skepticism in their ability to provide new information,
which could not be obtained through other methods such as interviews. In one survey clinicians
reported doubt that such instruments would provide a benefit over clinical judgment (Jensen-Doss
& Hawley, 2010). Some clinicians also reported skepticism of the reliability and validity of
assessment measures. Overall, however, the most negative views of standardized assessment
revolved around practicality. Practicality concerns were found to be the only predictor of
assessment tools use.
Should such measures be written off as impractical? To establish that, one must weigh the
cost and benefits of assessment tools. These will vary depending on the measure, but let us first
examine the big picture. Unstructured or semi-structured interviews remain the most common
assessment tool (Jensen-Doss & Hawley, 2010). They are flexible, and allow for in-depth and
personalized assessment. However, they have low validity and are prone to bias. Adding
standardized assessment measures to unstructured or semi-structured interviews could provide a
more well-rounded view. The two complement each other well. Assessment tools would add an
element of empiricism while reducing bias; the interview would add an element of client-centered
discussion while filling in any gaps of standardized assessment.
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Standardized assessment tools also provide a method for reducing clinician bias. Beidas et
al. (2015) describe the assessment process as “inherently a decision-making task fraught with
biases (p. 2, lines 8-9)”. Even experienced and competent clinicians are subject to confirmatory
bias and cognitive heuristics. EBA, however, could help to minimize these issues. When used for
progress tracking, EBA can also provide feedback for clinicians. It can aid in the evaluation of
treatment and allow for best practice. The APA is currently examining the utility of evidencebased assessment tools in a shift towards a dimensional view of disorders (Bastiaens & Galus,
2017). A handful of measures were included in the Diagnostic and Statistical Manuel-5 (DSM-5),
and listed as “emerging measures”. Such measures could be used to assess the severity of
symptoms for a wide array of disorders.
Clearly, EBA has a lot to offer. Yet, as previously discussed, practical concerns can prevent
assessment tools from being used. Beidas et al. (2015) list a number of factors to consider, which
affect the practicality of an instrument. They state that any assessment tool must be “brief, low
cost, valid, reliable, applicable, useful, actionable, and straightforward to administer, score and
interpret” (Beidas et al., 2015, p. 3). While this is a rather long list, it does provide many important
factors to look for. Instruments that meet this description would provide beneficial information
with relatively few drawbacks. A wide array of assessment tools is available, many of which do
fit these factors and many of which do not. Beidas et al. report throwing out over 100 instruments
in their study, which did not meet the above factors. For this paper, three instruments were chosen
based on their popularity and applicability. Beck’s Depression Inventory-II, the Patient Health
Questionnaire-9, and the Generalized Anxiety Disorder 7-item scale are three of the most used
assessment tools. They represent common disorders—depression and anxiety—making them
widely applicable. They have also been used in a variety of settings, such as in-patient units, outpatient clinics, and primary care offices. In order to assess their usefulness as evidence-based
assessment tools, it is important that their psychometric properties be analyzed.
BECK’S DEPRESSION INVENTORY-II
Beck’s Depression Inventory-II (BDI-II) is a highly popular example of an assessment tool.
It is a self-report measure of depressive symptoms for individuals age 13 and up (Segal et al.,
2008). It screens for depressive symptoms present over the last 2 weeks. The items were modeled
after the Diagnostic and Statistical Manuel of Mental Disorders fourth edition (DSM-IV) criteria
for a major depressive episode such as depressed mood, anhedonia, low energy, and changes in
weight or sleep (Wang & Gorenstein, 2013). The items in the BDI-II are also consistent with the
updated version of the DSM, the DSM-5, as the criteria for major depressive episodes were not
changed (American Psychiatric Association [APA], 2013). The measure consists of 21 items, each
with a 4-point Likert-type scale. Higher scores indicate higher levels of depression.
Overall, the BDI-II has been found to show excellent reliability. A meta-analysis revealed
internal consistency averaging around 0.90, which is considered excellent (Wang & Gorenstein,
2013). It was found to range moderately but remained very good to excellent in all samples. Segal
et al. (2008) found that the internal consistency was slightly higher for younger adults compared
to older adults, but that it was very good to excellent in both cases. The individual items which
had the strongest correlation with the total scores were related to loss of interest, loss of pleasure,
and sadness. Test-retest reliability was also stable. Coefficients ranged from 0.73-0.96, which is
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considered excellent (Wang & Gorenstein, 2013). Longer intervals between applications were
associated with smaller correlations between test scores. This is expected, because depressive
symptoms can decrease over time even without intervention. There is also some evidence that
decreases in retest scores are due to measurement effects (Wang & Gorenstein, 2013). This
suggests that continued re-application of the BDI-II in healthcare settings may underestimate the
level of depressive symptoms. The measurement effect appears to be relatively small, but it is
worth noting. Overall the BDI-II has excellent internal consistency and test-retest reliability.
Construct validity is another important factor to consider. It refers to the ability of a test to
measure the concept that it is intended to measure. The construct validity of the BDI-II is typically
assessed using confirmatory factor analysis. Some debate remains over whether a two-factor or a
single factor structure is a better fit for the data. Some literature suggests that the BDI-II taps into
two factors, cognitive-affective and somatic-vegetative (Wang & Gorenstein, 2013). Cognitiveaffective items include statements about self-criticism, irritability, guilt, and hopelessness.
Somatic-vegetative items include statements about changes in appetite, difficulty concentrating,
feelings of restlessness, and loss of energy. This was the factor structure suggested by the original
authors, and it has been well supported. However, some studies have found that the two-factor
model was not a good fit using confirmatory factor analysis (Segal et al., 2008). 20 out of the 21
items were found to load saliently onto a single factor, suggesting that there is no need to make a
distinction between cognitive and somatic items. Segal et al. (2008) claimed that the two factors
were not “conceptually meaningful or practically useful” (p. 15). If the two factors are indeed
distinct, they appear to be highly related, with between-factor correlation ranging from 0.49 to
0.87 (Wang & Gorenstein, 2013). Thus the cognitive-affective and somatic-vegetative aspects of
the BDI-II are closely related, and possibly tap into the same factor.
Convergent validity for BDI-II has been well established (Segal et al., 2008). It has
relatively strong, positive correlations with other measures of depression, including the Center for
Epidemiologic Studies Depression Scale (CES-D), the Coolidge Axis II Inventory (CATI)
depression subscale, the Depression Anxiety Stress Scales depression subscale (DASS-D), and the
Symptom Checklist-90 depression subscale (SCL-90-D; Segal et al., 2008; Wang & Gorenstein,
2013). It also has strong positive correlations with measures of general psychopathology and
negative correlations with measures of psychological well-being (Wang & Gorenstein, 2013).
Correlations with measures of anxiety are also quite strong, ranging from 0.53 to 0.67 (Segal et
al., 2008). This suggests the BDI-II offers poor discriminant validity between depressive
symptoms and anxiety-based symptoms. Given the overlap in symptoms and the high rates of
comorbidity (Wang & Gorenstein, 2013), it is unsurprising that a short assessment tool would be
unequipped for distinguishing between the two. However, these strong correlations with anxiety
and general psychopathology suggest that the BDI-II should not be used as a sole indicator of
depression. Other disorders, physical illness, or social problems could also cause a high score. The
measure’s high face validity also brings the possibility of malingering (Segal et al., 2008). So while
the BDI-II clearly has strong convergent validity with other measures of depression, a more
thorough assessment is needed to establish if a diagnosis of depression is merited.
Some divergent validity has been established as well. Divergent validity refers to the
ability of the test to avoid being influenced by concepts that it was not intended to measure. Low
correlations have been found between the BDI-II and measures of drug and alcohol use (Wang &
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Gorenstein, 2013). This an important type of divergent validity to establish, because the DSM-5
criteria for a depressive episode require that it not be due to the physiological effects of a substance
or substance abuse (APA, 2013). It is important that any assessment tool of depression does not
inadvertently measure drug or alcohol use.
Criterion validity examines how well a test correlates with a target criterion. For the BDIII, criterion validity assesses how well it predicts a diagnosis of depression. The sensitivity of the
measure was found to be 0.70 when compared with structured intake interviews. Wang &
Gorenstein (2013) consider this the most important indicator, because it suggests a low level of
false negatives, or undetected cases of depression. False negatives are more detrimental than false
positives because the suffering individual is unlikely to get help if the depressive symptoms go
unrecognized. False positives are unhelpful, but they can be ruled out after further examination.
The area under the ROC curve, which indicates diagnostic accuracy was 75% or higher, with an
average of 87%. This suggests that the BDI-II has an acceptable to excellent ability to discriminate
between individuals with depression and individuals without depression.
Wang and Gorenstein (2013) also suggest having different criterion-referenced cutoff
points for different populations. They found that a score of 22 or higher was most predictive in
psychiatric samples, while cutoffs of 10 and 15 were most predictive in non-clinical and medical
samples, respectively. This is in line with the original authors’ recommendation to develop local
norms for the interpretation of scores. Psychiatric samples had significantly higher mean scores
than medical or nonclinical samples, which is expected given that psychiatric samples are
definitionally experiencing higher levels of psychiatric distress. Higher criterion-referenced cutoff
points were needed to enhance specificity. The cutoff that should be used for intervention should
depend, therefore, on the setting in which it is being used.
Overall, Beck’s Depression Inventory provides a short, simple, reliable, and validated
measure of depressive symptoms. It has excellent internal consistency and test-retest reliability, it
correlates strongly with other measures of depression, and it is able to predict diagnoses of
depression in both psychiatric and nonpsychiatric samples. There is a unanimous consensus that
the BDI-II works well as a screening tool, and should be accompanied by other assessment
methods, such as intake interviews (Segal et al., 2008). The BDI-II can provide psychometrically
sound information on depressive symptoms, which is useful for the detection of cases, treatment
planning, and progress monitoring.
One of the major disadvantages of the BDI-II is that it is copyrighted and must be obtained
from the publisher, which prevents more widespread use (Wang & Gorenstein, 2013). A plethora
of other measures of depression is available for free, such as the Patient Health Questionnaire
depression module (PHQ-9). But does this measure hold up compared to the BDI-II? Is it
psychometrically sound?
PATIENT HEALTH QUESTIONNAIRE-9
The PHQ-9 was developed to screen for depression in primary care settings (Gilbody et
al., 2007). It consists of 9 self-report items that are based on the diagnostic criteria for a major
depressive episode as defined in the DSM-IV. It is a Likert-type scale, with items scored 0-3. PHQ-

University of Nebraska at Kearney Undergraduate Research Journal, Volume 25 – 2021

78

Alea Reifenrath

Assessment Tools in Clinical and Counseling Psychology

9 refers to the depression module of the Patient Health Questionnaire. The questionnaire as a whole
consists of 59 items that screen for a variety of mental health issues, such as alcohol abuse, bulimia
nervosa, anxiety, and panic attacks (Spritzer et al., 1999). The modules can be used separately or
as a whole, depending on the purpose of the assessment and the available time to complete it. The
PHQ-9 can provide a measure of the presence and severity of depressive symptoms. The
instruction manual recommends treating scores of 10 or more as a “yellow flag”, indicating
moderate levels of depressive symptoms and a potentially clinically significant condition. A score
of 15 or more represents a “red flag”, indicating high levels of depression that should receive
immediate assessment and possibly treatment. Moderate and high scores should prompt further
assessment, including a clinical interview.
The reliability of the PHQ-9 is well established. Internal consistency of the measure has
been found to be around 0.87, which is considered very good (Beard et al., 2016). The test-retest
reliability was found to 0.78 for a 2-week interval. This decreased with longer intervals, but as
with the BDI-II, such a decrease is expected. Depressive symptoms tend to improve over time, so
this decrease is likely due to the instrument picking up on a reduction of symptoms. Overall. it
appears to be a stable measure.
The content validity of the PHQ-9 has been assessed using confirmatory factor analysis. It
appears to have a two-factor structure, with one factor tapping into cognitive/affective traits of
depression and the other tapping into somatic traits (Beard et al., 2016). The cognitive/affective
factor includes items that relate to anhedonia, feelings of hopelessness, and feelings of failure. The
somatic factor includes items that relate to change in sleep, changes in appetite, and restlessness.
Similar to BDI-II, there is some debate over whether these represent two separate factors or
whether they load onto the same overarching factor. The two-factor model accounts for around
60% of the variance.
The construct validity of the PHQ-9 has also been established. It correlates strongly with
other well-established measures of depression, such as BDI-II and the Center for Epidemiologic
Studies Depression Scale (CES-D), with correlations around 0.80 (Beard et al., 2016). The PHQ9 also correlates strongly with measures of anxiety, such as the anxiety scale of the PHQ. Pearson’s
r values are around 0.60. As with BDI-II, high correlations between measures of depression and
anxiety are unsurprising given the high comorbidity rates and the overlap of symptoms. This high
correlation is therefore not particularly concerning, although it is important to note that individuals
with high levels of anxiety may score highly on the PHQ-9 because of it. Questionnaire
administrators should be aware that a moderate or high score on the PHQ-9 could result from
mental health issues other than depression.
Criterion validity has been established in multiple ways. Patients in a behavioral health
unit, who were experiencing current major depressive episodes, scored significantly higher than
patients who were not experiencing current major depressive episodes (Beard et al., 2016). This
suggests that the PHQ-9 was able to predict current major depressive episodes, which provides
concurrent predictive validity for the measure. The sensitivity and specificity of the measure have
also been examined. A meta-analysis found the average sensitivity in a variety of settings to be
0.92 (Gilbody et al., 2007). In other words, the measure accurately detects cases of existing
depressive symptoms in 92% of cases. This is quite a bit higher than the specificity of the BDI-II,
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which was found to have a sensitivity of around 0.70 (Wang & Gorenstein, 2013). The PHQ-9 was
more likely to detect existing depressive symptoms than BDI-II. The average specificity of the
PHQ-9 was found to be around 0.80 (Gilbody et al., 2007). This means that the PHQ-9 will
correctly reject the presence of depressive symptoms 80% of the time, while falsely identifying an
individual as having depressive symptoms 20% of the time. High sensitivity is considered more
important than high specificity in this situation, because further evaluation can reduce the number
of false positives. Undetected cases of depression, however, can bring about high levels of distress,
dysfunction, and danger to an individual. The PHQ-9 displays exceptionally high levels of both
specificity and sensitivity, which make it an attractive measure.
It is also sensitive to change, which is important in long-term settings. Significant pre-post
changes in scores were found upon discharge from an in-patient behavioral health hospital (Beard
et al., 2016). Large effect sizes were observable after only 1-2 weeks of Cognitive-Behavioral
Therapy. These effect sizes were found to be similar to the changes observable in CES-D scores.
This suggests that the PHQ-9 is able to detect reductions in depressive symptoms. Self-report
measures of treatment reflection also support this. Patients with significant reductions in PHQ-9
scores at discharge were more likely to report improvement than patients without significantly
lower scores. Therefore, the PHQ-9 is a useful measure of symptom severity and improvement
due to treatment. It can be used to assess treatment in psychiatric settings.
The PHQ-9 provides a valid and reliable measure of depressive symptoms. It is also
exceptionally brief and easy to use. It was originally designed to screen for depression in primary
care settings, although it has been found to be similarly useful in psychiatric and hospital settings
(Gilbody et al., 2007). It can be used to detect depression, assess severity, aid in initial treatment
decisions, and measure treatment outcome (Spritzer et al., 1999). Its brevity and accessibility,
along with its solid psychometrics, allow the PHQ-9 to be widely used. The PHQ-9 is so well
regarded that it is listed in the DSM-5 as a recommended measure of depression severity (APA,
2013). It is important to note that the PHQ-9 alone should not be used to diagnose depression. It
should only be used to supplement other aspects of assessment. However, it is a valuable evidencebased addition for screening or treating depression in a variety of settings.
GENERALIZED ANXIETY DISORDER 7-ITEM SCALE
Other similar measures exist for common diagnoses, such as anxiety disorders. The
Generalized Anxiety Disorder 7-item scale (GAD-7) was created in conjunction with the PHQ-9
(Spritzer et al., 2006). It is extremely brief, consisting of just 7 self-report items on a 4-point Likerttype scale (Beard et al., 2016). Similar to the PHQ-9, the items are based on DSM-IV criteria.
They focus on symptoms related to Generalized Anxiety Disorder (GAD), such as restlessness,
irritability, and uncontrolled worry (Spritzer et al., 2006). The items are consistent with the latest
version of the DSM, although they are slightly more vague than the DSM-5 criteria. For example,
one item on the GAD-7 mentions worrying about “different things” while the DSM-5 specifically
mentions the worry must occur in multiple facets of life (APA, 2013). The GAD-7 also has a
different time frame. It focuses on symptoms over the last two weeks, rather than the 6 months
mandated by the DSM-5. This suggests that individuals may score highly on the assessment but
not qualify for a diagnosis of GAD.
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However, high scores could indicate other mental health issues, particularly other anxiety
disorders. For example, an individual who has been experiencing extreme worry for the past month
would likely score highly on the GAD-7. They would not qualify for a diagnosis of GAD, but they
could potentially be diagnosed with an unspecified anxiety disorder or other specified anxiety
disorder. Individuals suffering from a specific phobia or social anxiety disorder would similarly
be likely to score highly on the GAD-7 because it does not examine the source or setting of the
symptoms. So while the GAD-7 does not discriminate well between the various anxiety disorders,
it is well supported as a transdiagnostic measure of anxiety (Beard & Bjorgvinsson, 2014).
The reliability of the measure appears to be reasonable. Internal consistency was found to
be 0.88, which is considered very good (Beard & Bjorgvinsson, 2014). Other reliability estimates
were found to be around 0.85 (Rutter & Brown, 2017). High reliability estimates were found even
when presented in different languages and settings (such as primary care, psychiatric inpatient,
and outpatient). Overall, its stability has been well-established.
Construct validity of the GAD-7 has been examined using confirmatory factor analysis. A
one-factor model did not fit the data well (Beard & Bjorgvinsson, 2014; Rutter & Brown, 2017).
Somatic items, such as difficulty relaxing and restlessness, were found to load onto a separate
factor. Rutter and Brown (2017), however, proposed a revised one-factor model that fit the data
well. Factor loadings were consistent across gender and race.
Convergent validity for the GAD-7 has been well documented. It has been found to have
strong, positive correlations with established measures of stress, anxiety, and worry (such as the
Depression Anxiety and Stress Scales and the Penn State Worry questionnaire; Rutter & Brown,
2017). It also had a moderate negative correlation with psychological well-being and a moderate
positive correlation with depression (Beard & Bjorgvinsson, 2014). Rutter and Brown (2017)
examined measures of depression and obsessive-compulsive disorder (OCD) for discriminate
validity. They found moderate correlations with the GAD-7 for each. However, these disorders are
highly related to GAD and it is fairly unsurprising that a moderate correlation would exist. Rutter
and Brown chose measures of depression and OCD to examine the GAD-7’s ability (or lack
thereof) to discriminate between disorders. They do, however, point out that the disorders are
phenotypically similar and frequently comorbid. A strong correlation with measures of anxiety
and worry, as well as moderate correlations with measures of OCD and depression, suggest that
the GAD-7 has some ability to differentiate between disorders but that it is easily influenced by
other mental health issues.
This weakness in the GAD-7 can also be seen when examining the specificity and
sensitivity of the measure. The recommended cutoff score for further evaluation is 10 out of 21.
This cutoff was found to be reasonable for nonpsychiatric samples but resulted in high falsepositive rates in clinical psychiatric samples (Beard & Bjorgvinsson, 2014). A cutoff score of 10
resulted in fair sensitivity, but poor specificity in psychiatric samples. Considering the previously
mentioned correlations with depression and OCD, it is likely that the GAD-7 is influenced by other
disorders, which results in artificially high indicators of anxiety. It is also worth noting that
individuals entering an inpatient program are likely to be experiencing high levels of stress and
anxiety related to the situation and setting. They may be more likely to report that they have “felt
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nervous” or “had trouble relaxing” over the last few days because the situation itself could be
creating stress and anxiety.
Nonetheless, the GAD-7 has the worst specificity of any measure listed in this paper. Rutter
and Brown (2017) claimed that no cutoff score was able to adequately balance sensitivity and
specificity. It is clear that, at least in psychiatric settings, the GAD-7 performs poorly as a screening
tool for GAD. It lacks the ability to adequately distinguish individuals with GAD from those
without. It has been found to perform much better as a screener in primary care settings, which is
what it was originally created for (Beard & Bjorgvinsson, 2014).
While the GAD-7 performs poorly as a screener in psychiatric settings, it has had success
as a measure of anxiety severity. Pre-post changes with large effect sizes were evident in
individuals with GAD, post-traumatic stress disorder, and panic disorder following inpatient
treatment (Beard & Bjorgvinsson, 2014). Patients who reported “very much” improvement also
had significantly larger reductions in scores than patients who did not report high levels of
improvement. Scores decreased an average of 4 points following inpatient treatment, which shows
that the GAD-7 is sensitive to change even over a short period of time (Rutter & Brown, 2017).
The GAD-7 appears to be a psychometrically sound measure of the severity of anxiety in a broad
sense, although it is less successful at screening for the presence or absence of GAD.
Like the PHQ-9, the GAD-7 is short, easy to score, and publicly available. This can make
it attractive as a quick and easy addition in a variety of settings. It is also psychometrically sound.
It has very good reliability, and evidence of construct and convergent validity. Its uses vary
somewhat depending on the setting. In primary care settings it can provide a quick and efficient
screening for anxiety disorders (Rutter & Brown, 2017). Because anxiety is a relatively common
mental health concern, it can be helpful to assess and screen for it in the general population. In
outpatient or inpatient psychiatric settings, the GAD-7 should not be used as a screening tool, as it
fails to discriminate well between disorders. However, individuals in these settings have already
been identified as needing treatment and will be going through a more thorough assessment to
establish a diagnosis. Screening tools, therefore, are less necessary. The GAD-7 does provide a
measure of anxiety severity, which can be informative at the onset of treatment to establish which
route to take, as well as throughout treatment, to establish the effectiveness of the treatment.
Although the GAD-7 has some weaknesses, it is a well-supported assessment tool that can provide
supplemental information in a variety of settings.
CONCLUSION
The BDI-II, PHQ-9, and GAD-7 are three examples of a myriad of available assessment
tools. The BDI-II is a highly popular instrument, with strong psychometrics. The PHQ-9 provides
an alternative to the BDI-II, which is free to the public and still psychometrically sound. The GAD7 was made in conjunction with the PHQ-9. While it has some weaknesses, it provides a reliable
and valid measure of anxiety. These three instruments were chosen due to their popularity, ease of
administration, and potential for even greater use. The broad areas of anxiety and depression
represent extremely common disorders. Because of their high prevalence, evidence-based
assessment tools catered toward depression and anxiety could be useful in primary care offices,
inpatient clinics, and outpatient facilities. These measures take only minutes to complete and are
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easy to score and interpret. This reduces the strain on time and resources that longer, more complex
measures would create. This simplicity and brevity, along with solid psychometric properties,
make these measures practical additions to the assessment process. Thus, they address the main
concerns of practitioners—that the measures be valid, reliable, practical, and useful. These
instruments, along with many others, show that EBA is possible and plausible. The term
“evidence-based” should not be reserved for treatment alone, but rather it should be integrated into
all parts of the therapeutic process.
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